Historical salary details - Mr. Rory B. Riggs, Chairman of the Board of Company and Cibus Global, Cibus Inc - Ordinary Shares - Class A
Mr. Rory B. Riggs is the Chairman of the Board of Company and Cibus Global of Cibus Inc - Ordinary Shares - Class A.
Mr. Rory B. Riggs
Chairman of the Board of Company and Cibus Global
-
Gross Remuneration
-
Current Company
Cibus Inc - Ordinary Shares - Class A
| YEAR | COMPANY | POSITION | SALARY | INCREMENT |
|---|---|---|---|---|
| 2025 | Cibus Inc - Ordinary Shares - Class A | Chairman of the Board of Company and Cibus Global | - | - |
| 2024 | Intra-Cellular Therapies Inc | Independent Director | - | - |
| 2023 | Intra-Cellular Therapies Inc | Independent Director | 470.5 K | -36.5 % |
| 2023 | Royalty Pharma plc - Ordinary Shares - Class A | Independent Director | 318.5 K | - |
| 2023 | Cibus Inc - Ordinary Shares - Class A | Chairman of the Board and Chief Exectuive Officer | - | - |
| 2022 | Intra-Cellular Therapies Inc | Independent Director | 741.2 K | 5.0 % |
| 2022 | FibroGen Inc | Independent Director | 26.5 K | -89.2 % |
| 2022 | Royalty Pharma plc - Ordinary Shares - Class A | Independent Director | - | - |
| 2022 | FibroGen Inc | Independent Director | - | - |
| 2021 | Intra-Cellular Therapies Inc | Independent Director | 705.7 K | 92.8 % |
| 2021 | FibroGen Inc | Independent Director | 246.6 K | -32.4 % |
| 2021 | Royalty Pharma plc - Ordinary Shares - Class A | Director | - | - |
| 2020 | Intra-Cellular Therapies Inc | Independent Director | 366.1 K | 52.1 % |
| 2020 | FibroGen Inc | Independent Director | 364.6 K | -14.8 % |
| 2020 | Royalty Pharma plc - Ordinary Shares - Class A | Director | - | - |
| 2019 | FibroGen Inc | Independent Director | 427.8 K | 65.8 % |
| 2019 | Intra-Cellular Therapies Inc | Independent Director | 240.7 K | -30.7 % |
| 2019 | Royalty Pharma plc - Ordinary Shares - Class A | Director | - | - |
| 2018 | Intra-Cellular Therapies Inc | Independent Director | 347.3 K | 45.5 % |
| 2018 | FibroGen Inc | Independent Director | 258.0 K | -5.3 % |
| 2017 | FibroGen Inc | Independent Director | 272.4 K | 34.2 % |
| 2017 | Intra-Cellular Therapies Inc | Independent Director | 238.6 K | -57.6 % |
| 2016 | Intra-Cellular Therapies Inc | Independent Director | 562.9 K | 41.5 % |
| 2016 | FibroGen Inc | Independent Director | 203.0 K | 6.3 % |
| 2015 | Intra-Cellular Therapies Inc | Independent Director | 397.8 K | -24.2 % |
| 2015 | FibroGen Inc | Independent Director | 191.0 K | -14.7 % |
| 2014 | Intra-Cellular Therapies Inc | Independent Director | 524.7 K | - |
| 2014 | FibroGen Inc | Independent Director | 224.0 K | - |
| 2013 | FibroGen Inc | Independent Director | - | - |
| 2013 | Intra-Cellular Therapies Inc | Independent Director | - | - |